Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Julphar
Covington
Daiichi Sankyo
Teva
Cerilliant
Queensland Health
Medtronic
Merck

Generated: February 25, 2018

DrugPatentWatch Database Preview

Doripenem - Generic Drug Details

« Back to Dashboard

What are the generic sources for doripenem and what is the scope of doripenem freedom to operate?

Doripenem
is the generic ingredient in one branded drug marketed by Shionogi Inc and is included in one NDA. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Doripenem has sixteen patent family members in fourteen countries.

There are five drug master file entries for doripenem. Two suppliers are listed for this compound.
Pharmacology for doripenem
Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial

US Patents and Regulatory Information for doripenem

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for doripenem

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 ➤ Sign Up ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for doripenem

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for doripenem

Supplementary Protection Certificates for doripenem

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00003 Denmark ➤ Sign Up PRODUCT NAME: DORIPENEM, HERUNDER DORIPENEMMONOHYDRAT; REG. NO/DATE: EU/1/08/467/001 20080725
0528678/01 Switzerland ➤ Sign Up PRODUCT NAME: DORIPENEMUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58667 19.10.2009
00374 Netherlands ➤ Sign Up PRODUCT NAME: DORIPENEM; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
C/GB09/006 United Kingdom ➤ Sign Up PRODUCT NAME: DORIPENEM; REGISTERED: UK EU/1/08/467/001 20080725
3 Finland ➤ Sign Up
09/002 Ireland ➤ Sign Up PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
C0005 France ➤ Sign Up PRODUCT NAME: DORIPENEME; REGISTRATION NO/DATE IN FRANCE: EU/1/07/467/001 DU 20080725; REGISTRATION NO/DATE AT EEC: EU/1/08/467/001 DU 20080725
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Moodys
US Department of Justice
Covington
Johnson and Johnson
Baxter
Cerilliant
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot